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1. Introduction
The use of specific chemicals to treat specific diseases and disorders dates to 1910 when Paul
Ehrlich and Sahachiro Hata discovered that salvarsan, also known as arsphenamine and
compound 606, killed the microorganism that caused syphilis. Their research relied on ani‐
mal models of syphilis as, even currently, syphilis cannot be grown in culture medium. Ar‐
sphenamine was the first synthetic drug to actually target and kill a disease-causing
organism and is credited with starting the pharmaceutical age. Ehrlich is also credited with
coining the term magic bullet in reference to a drug that would kill a microorganism without
damaging or otherwise affecting the host of the microorganism: the patient. As I will ex‐
plain, despite being an inspirational concept that led to advances in science and medicine,
the notion of a magic bullet proved incomplete. Salvarsan and Ehrlich’s concept of a magic
bullet are important to current concepts in drug testing because: 1) salvarsan was initially
called compound 606 as it was the 606th compound tested on animals in an attempt to find a
treatment for syphilis; and 2) the concept of a magic bullet was based on the scientific proc‐
ess known as reductionism. In this chapter, I will explore the reductionist approach of using
animal models in drug development, especially in toxicity testing.
2. Reductionism and complexity
The use of animals as models for human anatomy and pathophysiology dates back millen‐
nia but the modern version began with Claude Bernard in the 19th century. Bernard was a
firm believer in the reductionist approach to medical science and that approach has indeed
served biomedical science well for decades. A review of reductionism will allow us to con‐
trast this approach to understanding the material universe with systems biology, which is
needed in order to fully understand complex living systems. [1-13]
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Ernst Mayr defines reductionism as: “The belief that the higher levels of integration of a
complex system can be fully explained through a knowledge of the smallest components.”
[[14] p290] For example, physics attempts to describe the universe in terms of a few elemen‐
tary particles, and the relationships among them. Reductionism has been very successful in
describing many aspects of the material universe, including allowing successful predictions
to be made. Reductionism is associated with Newton, Descartes, and determinism and the
reliance on animal models in medical science arose during the time of Newtonian physics
vis-à-vis reductionism and determinism. Newton said: “Therefore to the same natural ef‐
fects we must, as far as possible, assign the same causes” and went on to explain that this
rule applies “to respiration in a man and in a beast, the descent of stones in Europe and
America, the light of our culinary fire and of the sun, the reflection of light in the earth and
in the planets.”[[15] p3-5] Both Newton and Claude Bernard subscribed to the position that
similar causes yield similar effects. Indeed, this concept was one of the breakthroughs that
led to the systematic method of inquiry known as the resoluto-compositive method or method
of analysis and synthesis. This concept of causal determinism rests on two claims. First, all
events have causes, and second, for qualitatively identical systems, the same cause is fol‐
lowed by the same effect. Causal determinism is a presupposition of much scientific activity.
The idea that results in the laboratory can be extended to form expectations about qualita‐
tively similar systems outside the laboratory is embodied in this idea, as is the claim that
experiments should be replicable. [16] This was how science viewed the universe, including
animate bodies, when the animal model was embraced by science in the 19th century.
Claude Bernard was a strict causal determinist, meaning that if X caused Y in a monkey it
was also cause Y in a human. Bernard stated: “Physiologists... deal with just one thing, the
properties of living matter and the mechanism of life, in whatever form it shows itself. For
them genus, species and class no longer exist. There are only living beings; and if they
choose one of them for study, that is usually for convenience in experimentation.”[[17] p
111] Further complicating matters, Bernard and many of his colleagues rejected the notion of
evolution put forth by Darwin. [17-19] Bernard thought that organs and other tissues were
interchangeable among animals and that all differences could be accounted for based on
scaling; the chief difference between humans and animals being a soul.[19] This thinking
persists even in recent times as exemplified by the baboon heart transplant in to the recipi‐
ent Baby Fae, performed by the creationist surgeon Leonard Bailey of Loma Linda Universi‐
ty in 1984. [[20] p162-3]
However, recent advances in other disciplines of science, namely chaos and complexity
along with evolutionary biology, have called into question the use of reductionism as the
sole factor in studying complex systems. Moreover, the developments in evolutionary biolo‐
gy and genetics are cause for further concern regarding the use of one complex evolved sys‐
tem, say a mouse, to predict responses to perturbations such as disease and drugs for
another differently evolved complex system, say a human. For example, we now under‐
stand that the same gene can be used in different ways among species and that knocking out
a gene in one species is not predictive for the function of that gene in another species.[21-27]
This has implications for drug development.
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Reductionism was  used  to  study simply  systems  as  opposed to  complex  systems.  Ani‐
mals, including humans, are complex systems and as such exhibit the characteristics list‐
ed below [from [28]].
1. Complex systems are robust, meaning they have the capacity to resist change. [8, 9,
29-35] This can be illustrated by the fact that knocking out a gene in one strain of mouse
may produce no noticeable effects.
2. Redundancy tends be  a  part  of  complex systems and may explain some aspects  of
robustness.  For  example,  many members  of  the kingdom Animalia  exhibit  gene re‐
dundancy. [8, 9, 29-35]
3. Different parts of a complex system are linked to and affect one another in a synergistic
manner. In other words, there is positive and negative feedback in a complex system.
[36] This is why overloading one part of a complex system with say vitamins, may not
result in a healthier individual. The feedback system results in the rest of the system
acting to simply excrete the unneeded vitamins.
4. Complex systems are also modular. But failure in one module does not necessarily
spread to the system as a whole as redundancy and robustness also exist. [37-40]
5. The modules do communicate though. For example, genes tend to be part of networks,
genes interact with proteins, proteins interact with other proteins and so on.
6. Complex systems communicate with their environment—are dynamic. [37-40]
7. Complex systems are very dependent upon initial conditions. [39] For example, very
small changes in genetic makeup can result in dramatic differences in response to per‐
turbations of the living system.
8. The causes and effects of the events that a complex system experiences are not propor‐
tional to each other. Perturbations to the system have effects that are nonlinear, in other
words large perturbations may result in no change while small perturbations may cause
havoc. [37-40]
9. The whole is greater than the sum of the parts. [1, 8, 9, 30, 39]
10. Complex systems have emergent properties. An emergent property cannot be predicted
by full knowledge of the component parts. For example, the formation of a flock of birds
and hurricanes are examples of emergent phenomenon as is perhaps consciousness. [39]
Reductionism is essentially divide and conquer. By dividing a system into its parts and ascer‐
taining the functions of all the parts of the system, one can deduce the function of the entire
system. The gears of a Swiss watch, for example, are capable of description on their own,
without reference to the system from which they are removed. Conversely, the individual
components of a complex system must be described based on the interaction of the parts. De‐
scribing individual components in isolation, regardless of how detailed such a description
is, cannot fully describe the complex system as a whole. The whole is greater than the sum
of the parts. A complex system must be described based on the organization of the individual
components. [41, 42]
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Miska states:
The basic analytical method that is behind most biomedical research can be traced back over 300 years to Descartes’s essay Dis‐
course on Method, which argued that an animal is a clock-like machine in which the parts and their relationships to one another
are precise and unchangeable, and in which causes and effects can be understood by taking the pieces apart. This so-called ‘reduc‐
tionist’ approach to understanding biology and medicine has been very productive, but is now up against problems that require
different frameworks, institutionally and intellectually. [43]
Nicolis & Prigogine defined complexity as the ability of a system “to switch between differ‐
ent modes of behavior as the environmental conditions are varied.”[44] In other words,
complex systems are able to adapt to their environments just as life on this planet has adapt‐
ed resulting in different species. But these adaptions mean that two complex systems that
were originally identical would now be less similar and behave differently in certain circum‐
stances. An example of this would be the susceptibility to disease between monozygotic
twins. [45-56] Van Regenmortel states:
Reductionists tend to disregard the fact that all biological systems possess so-called emergent properties that arise through the mul‐
tiple interconnections and relations existing between individual components of the system. These emergent, relational properties
do not exist in the constituent parts and they cannot be deduced or predicted from the properties of the individual, isolated compo‐
nents [[57]p258]. Examples of emergent properties are the viscosity of water (individual water molecules have no viscosity), the
colour of a chemical, a melody arising from notes, the saltiness of sodium chloride, the specificity of an antibody and the immuno‐
genicity of an antigen. [58]
Living complex systems are the result of various evolutionary processes and as such are ar‐
guably the most complex of all complex systems. Species differ because of the presence of dif‐
ferent genes, mutation in the same genes, a difference in the number of the same allele (copy
number variants), the same genes may be regulated or expressed differently, alternative
splicing, the presence of modifier or background genes, differences in gene networks and
protein networks, and convergent evolution where two species share a trait but the trait
evolved independently in each. Individuals of the same species may differ for many of the
above reasons but also because of dissimilarities in environmental exposures. [50] Impor‐
tantly, each of the above means that different species as well as individuals of the same spe‐
cies manifest differences in the initial conditions of their complex system. The above also
translates into differences in other characteristics of a complex system such as robustness
and redundancy.
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The progress in these two areas of science, complexity science and evolutionary biology, re‐
sults in strong theoretical concerns regarding the use of animals as predictive models in
drug development. We should expect animals and humans to share responses to perturba‐
tions at the level of organization where complex systems can be described as simple systems
but not for perturbations occurring at the level of organization where the system as a whole
is studied or where parts of the systems that are themselves complex are studied. I will next
examine the empirical evidence and place it in the context of these theoretical concerns.
3. Prediction in science
The third relevant advance in science since animal models were mandated for use in drug
development is the formal evaluation of animal models in terms of their predictive value for
humans. Animal models are used for ascertaining the properties of absorption, distribution,
metabolism, elimination and toxicity (ADMET). As all of these properties influence toxicity,
an examination of the ability of animal models to predict these properties is important, as is
the straightforward examination of animal models for toxicity itself. The answer to the ques‐
tion of the predictive ability of animal models was hinted at by the fact that Ehrlich and Ha‐
ta ultimately tested the 606th compound of a series in their attempt to find a treatment for
syphilis. Previous compounds had successfully treated syphilis in animal models but had
failed for various reasons in humans. Even salvarsan resulted in side effects in humans that
were unforeseen in animal models.
The ability to predict facts about the material universe is a hallmark of science. Hypotheses
are generated that make predictions about the phenomena under study and the success or
failure of these predictions can falsify or strengthen the hypothesis. This use of the term pre‐
dict differs from determining whether a modality, practice, or test is predictive for its pur‐
pose. For example, a CT scan of the chest is a predictive test for diagnosing a pneumothorax,
because the CT scan, as opposed to a chest x-ray, is successful in locating the pneumothorax
essentially 100% of the time. In order to evaluate a modality like CT scans, a blood test for
cancer, or even the use of dogs for catching drug smugglers in airports, the calculations in
table 1 are employed.
When evaluating the predictive value of methods, practices,  or tests for use in biomedi‐
cal science, positive predictive value (PPV) and negative predictive value (NPV) > 0.9 are
sought.  If  a  single  test  alone cannot  yield such high values then a  combination of  tests
can be evaluated in hopes that  the combination will  meet  the criteria.  Such evaluations
have been made for toxicity testing using animal models as well as other animal model-
based tests in drug development. Profound inter-species differences, as well as inter-indi‐
vidual  human differences,  have been revealed for absorption [[59]  p 8-10]  [[60]  pp 5,  9,
45,  50,  66-7,  90,  102-3,]  [61-64],  distribution [65,  66],  metabolism [67-77],  elimination [78,
79],  and toxicity  [64,  80-91],  which results  in  predictive  values  for  these  animal  models
that are far below those required in biomedical science. For example, Litchfield conduct‐
ed  a  classic  study  in  1962  comparing  toxicity  among  three  species:  humans,  rats,  and
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dogs.  The positive predictive values for the animal models were between 0.49 and 0.55.
[92] Similarly,  Suter compared toxicities for ergoloid mesylates,  bromocriptine,  ketotifen,
cyclosporine, FK 33-824, and clozapine in animals and humans. The sensitivity for toxici‐
ty for the animal tests was 0.52 and the predictive value positive was 0.31. [93] Fourches
et  al.  evaluated animal human data for 1061 compounds known to cause hepatotoxicity
in  humans  and  found  that  the  concordance  or  sensitivity  among  species  was  around
39-44%.[94] The positive and negative predictive values could not be calculated from the
article but would be well below 0.39. Smith and Caldwell studied twenty-three chemicals
and discovered that only four were metabolized the same in humans and rats. [70] Siet‐
sema  [95],  compared  the  oral  bioavailability  of  400  drugs  in  humans  with  three  other
species (see Figure 1) and concluded the data was consistent with a “scatter-gram.” Simi‐
lar results have been obtained from other studies.[84, 96-101]
Gold Standard
GS+ GS-
Test
T+ TP FP
T- FN TN
T+ = Test positive
T- = Test negative
T = True
F = False
P = Positive
N = Negative
GS+ = Gold standard positive
GS- = Gold standard negative
Sensitivity = TP/(TP+FN)
Specificity = TN/(FP+TN)
Positive Predictive Value = TP/(TP+FP)
Negative Predictive Value = TN/(FN+TN)
Table 1. Binomial classification method for calculating sensitivity, specificity, positive predictive value, and negative
predictive value when comparing a modality, practice, or test with a gold standard.
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Figure 1. Variation in bioavailability among species. (Based on data from [95].)
The fact that animal models lack predictive ability is well known.[102-110] This shortcoming
includes the inability of animal models to be predictive modalities for carcinogenicity.[111,
112] Salsburg stated: “Thus the lifetime feeding study in mice and rats appears to have less
than a 50% probability of finding known human carcinogens. On the basis of probability
theory, we would have been better off to toss a coin...”[111]
The general attitude in the drug development-related sciences reflects the empirical evi‐
dence. Cook et al:
Over many years now there has been a poor correlation between preclinical therapeutic findings and the eventual efficacy of these
[anti-cancer] compounds in clinical trials [109, 110].... The development of antineoplastics is a large investment by the private and
public sectors, however, the limited availability of predictive preclinical systems obscures our ability to select the therapeutics that
might succeed or fail during clinical investigation. [108]
Reuters quoted Francis Collins, Director of the NIH, as stating that: “about half of drugs that
work in animals may turn out to be toxic for people. And some drugs may in fact work in
people even if they fail in animals, meaning potentially important medicines could be reject‐
ed.”[113] Alan Oliff, former executive director for cancer research at Merck Research Labo‐
ratories in West Point, Pennsylvania asserted in 1997: “The fundamental problem in drug
discovery for cancer is that the [animal] model systems are not predictive at all.”[114] Björ‐
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quist and Sartipy stated: “Furthermore, the compound attrition rate is negatively affected by
the inability to predict toxicity and efficacy in humans. These shortcomings are in turn
caused by the use of experimental pre-clinical model systems that have a limited human
clinical relevance...”[115] In 2006, then U.S. Secretary of Health and Human Services Mike
Leavitt declared: “Currently, nine out of ten experimental drugs fail in clinical studies be‐
cause we cannot accurately predict how they will behave in people based on laboratory and
animal studies.”[116] Zielinska, writing in The Scientist supported the above, stating:
Mouse models that use transplants of human cancer have not had a great track record of predicting human responses to treatment
in the clinic. It’s been estimated that cancer drugs that enter clinical testing have a 95 percent rate of failing to make it to market,
in comparison to the 89 percent failure rate for all therapies... Indeed, “we had loads of models that were not predictive, that were
[in fact] seriously misleading,” says NCI’s Marks, also head of the Mouse Models of Human Cancers Consortium... [117]
The inability of animal models to predict human response has also increased the cost of
drug development as the cost for the 90-95% of drugs that fail must be recouped from the
ones that go to market.[91, 118-121] Lost revenue has also resulted from the drugs that
would have been marketable had animal models not derailed them in development. This
lack of predictive ability for animal models is largely to blame for the cost of new medica‐
tions and for the fact that the drug development pipeline is drying up.[115, 122, 123] Be‐
cause animal models fail to predict drugs destined to fail, these drugs go to clinical trials
and marketing which consumes roughly 95% of the cost for drug development.[124, 125]
Catherine Shaffer, Contributing Editor of Drug Discovery & Development, wrote in 2012:
“Drug development is an extremely costly endeavor. Estimates of the total expense of ad‐
vancing a new drug from the chemistry stage to the market are as high as $2 billion. Much
of that cost is attributable to drug failures late in development, after huge investments have
been made. Drugs are equally likely to fail at that stage for safety reasons, as for a lack of
efficacy, which is often well-established by the time large trials are launched.”[120] Roy esti‐
mates the real cost is even higher: “The true amount that companies spend per drug ap‐
proved is almost certainly even larger today. Matthew Herper of Forbes recently totaled
R&D spending from the 12 leading pharmaceutical companies from 1997 to 2011, and found
that they had spent $802 billion to gain approval for just 139 drugs: a staggering $5.8 billion
per drug.”[125] Kenneth Kaitin, director of Tuft’s Center for the Study of Drug commenting
on Pharma’s drying pipeline in the March 7, 2011 New York Times, stated: “This is panic
time, this is truly panic time for the industry.” Even when a drug does reach the market,
there is a great amount of uncertainty regarding safety. For example, over 1000 drugs that
reached the market were discovered to result in hepatotoxicity. [126]
Kirschner addressed this issue, asking: “could we develop a better way of predicting wheth‐
er a drug will work or have intolerable side effects?” He then explains the problem in terms
similar to what I have presented above:
New Insights into Toxicity and Drug Testing130
In part, this problem stems from the fact that we rarely have a situation in which one gene can be linked to one disease and targeted
by one drug. The nature of our biological system is that we have relatively few genes — say 20,000 basic core genes — that are
used over and over again in different contexts. So when we investigate targets, we need to better appreciate how these function in
different contexts. Moreover, there are many overlapping and redundant pathways, so we need to better understand genes not as
individual elements with individual functions but within the context of the circuits in which they operate. This approach requires
not just a wiring diagram, but a quantitative wiring diagram... [127]
4. This leads us to current efforts at improving drug development
4.1. Twenty-first century science
Today we have options for drug development and toxicity testing that did not exist until the
21st century, for example microdosing and pharmacogenomics. Two points need be empha‐
sized before I address these two advances, however. First, animal models fail to meet the
ends for which they are used; they are not predictive modalities for human response. There‐
fore using animal models is akin to relying on bloodletting as a treatment for cancer when
oncologists have no cures for the cancer in question. Just as bloodletting is not effective as a
treatment for cancer, regardless of whether or not other options are available, so employing
animal models as they are currently utilized is nonsensical.
Second,  technology is  available,  or  is  being developed,  that  will  at  least  predict  human
response  for  certain  properties  important  in  drug development.  However,  regardless  of
how much time is needed in order for these technologies to be developed, animal mod‐
els  are  simply ineffective and hence should be abandoned.  Lack of  effective technology
does  not  justify  the  utilization  of  methods  proven  to  be  ineffective.  Regardless  of  the
technologies available, drug development must be human-based both when reductionism
is  used  and  when  complexity  is  relevant.  Basing  drug  development  decisions  on  drug
targets identified from animal models has not been effective. Human tissues can be stud‐
ied instead and this will  allow targets to be established in a more reliable manner.  Hu‐
mans  must  also  be  studied  when  responses  to  drugs  are  occurring  at  higher  levels  of
organization; where the system is complex.
In 2006, the FDA approved microdosing for Phase 0 clinical trials.[128, 129] Microdosing
is the process whereby very small doses of a drug are administered to human volunteers
after  which  positron  emission  tomography  (PET)  and  accelerator  mass  spectrometry
(AMS) are  used to  assess  pharmacokinetic  (PK) data.[130-132]  While  animal  models  are
used  to  inform  the  dose  for  the  first  administration  of  the  drug,  the  usual  range  for
drugs  is  100ng to  100μg.  If  all  drugs  were  initially  administered  at  a  dose  of  1ng  and
subsequently increased, this would obviate the use of unreliable animal models and en‐
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sure  that  the  first-in-human  dose  was  lower  than  the  most  toxic  substance  currently
known.[133, 134] This would be a reliably safe method for conducing first-in-human tri‐
als. Although in practice microdosing is currently only used to evaluate PK (as opposed
to pharmacodynamics,  which is  abbreviated as PD),  it  could be used for  evaluating the
other properties of interest.  For example, by increasing the dose incrementally,  the drug
could be evaluated for toxicity. This solves the problem of unanticipated catastrophic re‐
actions such as occurred in the TGN1412 trial [135] and allows toxicity to be determined
very early in the drug development process. Long term carcinogenicity studies could not
be conducted in this fashion however animal models are not predictive for carcinogenici‐
ty  and  human  data  from  long  terms  use  is  the  de  facto  method  now  used.  Nothing
would  be  lost  by  eliminating  long-term carcinogenicity  studies  in  animals  until  predic‐
tive  technologies  are  developed.  According to  the  Centers  for  Disease  Control  and Pre‐
vention (CDC):  “Most  of  what  we know about  chemicals  and cancer  in  humans comes
from scientists'  observation of workers. The most significant exposures to cancer-causing
chemicals  have  occurred  in  workplaces  where  large  amounts  of  toxic  chemicals  have
been used regularly.”[136]
The  concept  of  microdosing,  used  in  combination  with  pharmacogenomics  (see  below)
would allow go-no go decisions to be made early and reliably in drug development as
well as matching drug to patient. The transition to full-scale clinical trials would also be
seamless.  As the dose was increased, an evaluation of efficacy could be made. By start‐
ing  the  dose  at  1ng  and  increasing,  the  entire  clinical  trial  could  be  conducted  much
more reliably and efficiently, drugs destined to fail could be eliminated earlier thus sav‐
ing money, and the drugs could be matched to genotype before being marketed thus fur‐
ther  saving  money  and  decreasing  side  effects.  This  leads  us  to  the  concepts  of
pharmacogenomics and personalized medicine.
Personalized medicine seeks to individualize medicine both in terms of treatment and di‐
agnosis  while  pharmacogenomics  matches  drugs  to  patients.  Rashmi  R  Shah,  previous
Senior Clinical Assessor, Medicines and Healthcare products Regulatory Agency, London
stated in 2005: “During the clinical use of a drug at present, a prescribing physician has
no means of predicting the response of an individual patient to a given drug. Invariably,
some patients fail to respond beneficially as expected whereas others experience adverse
drug  reactions  (ADRs).”[137]  Shah  echoed  comments  by  Allen  Roses,  then-worldwide
vice-president of  genetics at  GlaxoSmithKline (GSK),  who stated that  fewer than half  of
the  patients  prescribed  some  of  the  most  expensive  drugs  derived  any  benefit  from
them: “The vast majority of drugs - more than 90% - only work in 30 or 50% of the peo‐
ple.”[138]  That  individual  humans  respond  very  differently  to  disease  and  drugs  [139,
140],  including vaccines  [141,  142],  has  long been appreciated.  During the  Korean War,
Alving observed that  black soldiers  had an increased probability,  compared with white
soldiers,  of  developing anemia when from antimalarials.  This was discovered to be sec‐
ondary to a commonly occurring enzyme deficiency in the black soldiers.[143] Variation
in  disease  susceptibility  and  response  to  drugs  has  been  noted  to  exist  between  sexes
[144-150] and ethnic groups [151-159] as well as between monozygotic twins.[45-52, 56]
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Many advances have been made in linking drugs to genes, in part because of spin-offs from the
Human Genome Project. Differences between humans including single nucleotide polymor‐
phisms, copy number variants, differences the regulation and expression of the same genes,
differences in gene networks, and the influence of background genes can result in a drug being
efficacious for one patient but not another. Diseases vary intra-species as well. Michael Snyder,
chair of genetics at Stanford University School of Medicine, recently stated: “However, the
bulk of the differences among individuals are not found in the genes themselves, but in regions
we know relatively little about. Now we see that these differences profoundly impact protein
binding and gene expression.”[160, 161] Hunter et al studied a mouse model of cancer and dis‐
covered differences in metastatic efficiency secondary to background genes. Hunter et al:
Because all tumors were initiated by the same oncogenic event, differences in the metastasis microarray signature and metastatic
potential are probably due to genetic background effects rather than different combinations of oncogenic mutations. Consistent
with our observations in metastasis, several laboratories have shown similar strain differences with regard to oncogenesis, aging
and fertility in transgenic mouse models.[162-164] Data on both primary tumors and metastases reinforce the notion that tumori‐
genesis and metastasis are complex phenotypes involving both inherent genetic components and cellular responses to extrinsic
stimuli. [165]
Thein likewise stated: “As the defective genes for more and more genetic disorders become
unravelled, it is clear that patients with apparently identical genotypes can have many dif‐
ferent clinical conditions even in simple monogenic disorders.” Thein assessed β−thalasse‐
mia and noted that the clinical manifestations are very diverse, ranging from life threatening
to asymptomatic. Thein: “The remarkable phenotypic diversity of the β−thalassemias is pro‐
totypical of how a wide spectrum of disease severity can be generated in single gene disor‐
ders.... relating phenotype to genotype is complicated by the complex interaction of the
environment and other genetic factors at the secondary and tertiary levels...”[166]
Agarwal and Moorchung reinforce the above stating: “It is now increasingly apparent that
modifier genes have a considerable role to play in phenotypic variations of single-gene dis‐
orders.” This is due to factors such as: “Oligogenic disorders occur because of a second gene
modifying the action of a dominant gene. It is now certain that cancer occurs due to the ac‐
tion of the environment acting in combination with several genes.”[167] Friedman and Perri‐
mon explain that there are “hundreds of potential regulators of known signaling pathways.”
[168] PLoS Biology, in an editorial said the following about mouse models of autoimmune
diseases: “These results fall in line with mounting evidence that background genes are not
silent partners in gene-targeted disease models, but can themselves facilitate expression of
the disease. This finding underscores the notion that genes are not solitary, static entities;
their expression often depends on context. With genetically complex diseases, having the
requisite combination of susceptibility genes does not always lead to disease.”[169]
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Liu et al explain why the same genes can result in very outcomes:
A general view is that critical genes involved in biological pathways are highly conserved among species. To understand human
autoimmune diseases, a great deal of effort has been devoted to the study of murine models that mirror many pathologic properties
observed in the human disease. We have found that lymphocytes from humans with different autoimmune disease all carry a com‐
mon conserved gene expression profile. Therefore, we wanted to determine if lymphocytes from common murine models of autoim‐
mune disease carried a gene expression profile similar to the human profile and if both mouse models carried a shared gene
expression profile. We identified numerous differentially expressed genes (DEGs) in the autoimmune strains compared to non-
autoimmune strains. However, we found very little overlap in the gene expression profile between human autoimmune disease and
murine models of autoimmune disease and between different murine autoimmune models. Our research further confirms that mur‐
ine models of autoimmunity do not perfectly match human autoimmune diseases. [26]
Weiss et al continues this theme:
In contrast to these single gene effects, many drug treatment response phenotypes are complex, produced by multiple coding and
regulatory variants in multiple genes that often interact in a signalling pathway. In these cases, each variant could contribute to
the variance in the phenotype and there is no clear model of genetic inheritance. Genetic factors that influence whether a drug
treatment response is complex include mode of inheritance (recessive versus dominant or additive); pleiotropy; incomplete pene‐
trance; and epistasis, due to gene–environment interactions and environmental phenocopies. All of these factors contribute to the
complexity of the response phenotypes. [170]
Gabor Miklos states:
There is enormous phenotypic variation in the extent of human cancer phenotypes, even among family members inheriting the
same mutation in the adenomatous polyposis coli (APC) gene believed to be causal for colon cancer. In the experimental mouse
knockout of the catalytic gamma subunit of the phosphatidyl-3-OH kinase, there can be a high incidence of colorectal carcinomas or
no cancers at all, depending on the mouse strain in which the knockout is created, or into which the knockout is crossed... [27]
Because of advances alluded to above, society is seeing the death of the blockbuster and the
arrival of the “niche buster.” [171] Herscu et al write: “The era of the 'blockbuster drug mod‐
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el' is ending, and the development of personalized pharmaceutical system is on the rise.”
[172] This is also due to the fact that diseases are being categorized into more types and indi‐
viduals even within the same type react differently to drugs. Herscu et al write:
Diabetes mellitus, for example, was simply divided into juvenile or adult onset types for many years. Now we have pre-diabetes;
Type I, broken into immune-related and other causes; Type 2, broken into secretory defect and insulin-resistant types; and more
than 11 types that have been linked to specific genetic defects. However, even diabetic patients in a precisely defined category with
shared genetic markers differ because they exist at different points along the continuum of the disease depending on their diet,
exercise, comorbid conditions and other factors. These phenotypic dissimilarities are the source of inter-patient variability, which
confounds both clinical trials and treatment results. [172]
Iressa was one of the first medications administered to patients based on genotype. Iressa
did not perform well in clinical trials and was to be abandoned but clinicians were adamant
that it helped some people with cancer. By genotyping the patients that responded well to
Iressa, researchers were able to confirm that, in certain genotypes, Iressa was efficacious.
Numerous drug responses have been matched to specific mutations. [77, 173-176] The Per‐
sonalized Medicine Coalition notes that personalized medicine will allow patients and
physicians to:
• select optimal therapy and reduce "trial-and-error" medicine;
• reduce adverse drug reactions;
• improve the selection of drug targets;
• increase patient compliance with therapy;
• reduce the time, cost, and failure rate of clinical trials;
• revive drugs that failed clinical trials or were withdrawn from the market;
• avoid withdrawal of marketed drugs;
• shift the emphasis in medicine from reaction to prevention; and
• reduce the overall cost of healthcare.[177]
5. Conclusion
We are currently living in what will become known as the Age of Personalized Medicine.
While much has yet to be discovered, society is already benefitting from personalized medi‐
cine applied to specific drugs and diseases. Contrast this with using a different species in an
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attempt to predict human response to drugs and disease. While animals can be used in basic
science pursuits, empirical evidence from drug development, placed in the context of the
scientific theories of Complexity and Evolution, demands that animal testing be replaced
with human-based drug development. Implementing human-based testing early in the de‐
velopment process is how drugs should be developed now and it will be how drugs are de‐
veloped in the future.
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